Danhong injection inhibits the development of atherosclerosis in both apoe-/- and Ldlr-/- Mice

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 5, 2014, Pages 441-452

  Chen, Yuanli ^a   Liu, Mengyang ^a   Zhao, Tao ^b   Zhao, Buchang ^b   Jia, Lifu ^b   Zhu, Yan ^c   Zhang, Boli ^c   Gao, Xiumei ^c   Li, Guangliang ^a   Li, Xiaoju ^a   Xiang, Rong ^a   Han, Jihong ^a   Duan, Yajun ^a  

^a NANKAI UNIVERSITY   (China)

^b Shanxi Buchang Pharmaceutical Co Ltd   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

ABCA1; Atherosclerosis; Danhong injection; Inflammation; LDL cholesterol; Macrophages

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN E; DANHONG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PLANT MEDICINAL PRODUCT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ABC TRANSPORTER A1; ABCA1 PROTEIN, MOUSE; CHOLESTEROL; CYTOKINE; ESTRADIOL; HERBACEOUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROSIS; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SAFFLOWER; SALVIA MILTIORRHIZA; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; CELL LINE; CHOLESTEROL; CYTOKINES; DRUGS, CHINESE HERBAL; ESTRADIOL; FEMALE; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 84900800067     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000067     Document Type: Article

References (51)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104: 503-516.
3. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med. 2008;18:228-232.
4. Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology. 2012;217:492-502.
5. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
6. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
7. Ference BA, Mahajan N. The role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep. 2013;15:312.
8. Defesche JC. Low-density lipoprotein receptor-its structure, function, and mutations. Semin Vasc Med. 2004;4:5-11.
9. Liang K, Kim CH, Vaziri ND. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol. 2005;288:F539-F544.
10. Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375.
11. Lu R, Arakawa R, Ito-Osumi C, et al. ApoA-I facilitates ABCA1 recycle/ accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol. 2008;28: 1820-1824.
12. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis. 2010;211:361-370.
13. Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637.
14. Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42.
15. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
16. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
17. Du GH, Zhang JT. The general situation and progress of the modern research of red sage root (radix salviae miltiorrhizae). Herald Med. 2004; 23:335-360.
18. Jiang SY, Tong JC, Sun RY, et al. Meta-analysis of compound danshen dropping pills (DSP) in treating coronary heart disease angina. Prac Pharm Clin Remedies. 2007;10:334-337.
19. Li HX, Han SY, Wang XW, et al. Effect of the carthamins yellow from carthamus tinctorius L. On hemorheological disorders of blood stasis in rats. Food Chem Toxicol. 2009;47:1797-1802.
20. Liu F, Wei Y, Yang XZ, et al. Hypotensive effects of safflower yellow in spontaneously hypertensive rats and influence on plasma renin activity and angiotensin II level. Yao Xue Xue Bao. 1992;27:785-787.
21. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345-1359.
22. Yang JH, Ruan JY. Mutual action of salvia miltiorrhizae and western drugs. Chin J Integr Trad West Med. 1995;15:57-58.
23. Guo ML, Zhang HM, Zhang MY. Textual research of safflower. J Chin Med Mater. 1996;19:202-203.
24. Commission CP. Pharmacopoeia of the People's Republic of China. Beijing, PR China: People's Medical Publishing House; 2005;1:209-210.
25. Hong L. Danhong injection effects on vascular endothelial function in patients undergoing coronary artery stent implantation. J Clin Rehab Tissue Eng Res. 2010;14:2467-2470.
26. Liu J, Zhang D, Li J, et al. Effects of salvia miltiorrhiza and carthamus tinctorius aqueous extracts and compatibility on rat myocardial ischemic reperfusion injury. Zhongguo Zhong Yao Za Zhi. 2011;36:189-194.
27. Zhan Y, Xu JP, Liang JB, et al. Simultaneous LC-MS-MS analysis of danshensu, salvianolic acid b, and hydroxysafflor yellow a in beagle dog plasma, and application of the method to a pharmacokinetic study of danhong lyophilized powder for injection. Chromatographia. 2008;68:71-79.
28. Yue JR, Su FF. Preliminary observation of radix salviae miltiorrhizae and flos carthami tinctorii injection in the treatment of coronary heart disease. Shanxi J Med. 1990;19:105.
29. Liu HT, Wang YF, Olaleye O, et al. Characterization of in vivo antioxidant constituents and dual-standard quality assessment of danhong injection. Biomed Chromatogr. 2013;27:655-663.
30. Sun M, Zhang JJ, Shan JZ, et al. Clinical observation of Danhong injection (herbal TCM product from radix salviae miltiorrhizae and flos carthami tinctorii) in the treatment of traumatic intracranial hematoma. Phytomedicine. 2009;16:683-689.
31. Wang BZ, Cao MR, Zou WH, et al. The toxicological study of danhong injection. China Prac Med. 2008;3:27-29.
32. Gao LN, Cui YL, Wang QS, et al. Amelioration of danhong injection on the lipopolysaccharide-stimulated systemic acute inflammatory reaction via multi-target strategy. J Ethnopharmacol. 2013;149:772-782.
33. Han J, Hajjar DP, Tauras JM, et al. Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J Lipid Res. 1999;40:830-838.
34. Duan Y, Chen Y, Hu W, et al. Peroxisome proliferator-activated receptor g activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem. 2012;287:23667-23677.
35. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002;277:34182-34190.
36. Virmani R, Burke AP, Farb A, et al. Pathology of the unstable plaque. Prog Cardiovasc Dis. 2002;44:349-356.
37. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219:187-203.
38. Hansson GK, Libby P. The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol. 2006;6:508-519.
39. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-2150.
40. Bourdillon MC, Poston RN, Covacho C, et al. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE-/-/ ICAM-1-/-) fed a fat or a chow diet. Arterioscler Thromb Vasc Biol. 2000;20:2630-2635.
41. Branen L, Hovgaard L, Nitulescu M, et al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137-2142.
42. Guan Y, Yin Y, Zhu YR, et al. Dissection of mechanisms of a Chinese medicinal formula: Danhong injection therapy for myocardial ischemia/ reperfusion injury in vivo and in vitro. Evid Based Complement Alternat Med. 2013;2013:972370.
43. Wan LM, Tan L, Wang ZR, et al. Preventive and therapeutic effects of Danhong injection on lipopolysaccharide induced acute lung injury in mice. J Ethnopharmacol. 2013;149:352-359.
44. Zhou X, Yin Z, Guo X, et al. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem. 2010;285:6316-6326.
45. Costet P, Luo Y, Wang N, et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-28245.
46. Zhang Y, Beyer TP, Bramlett KS, et al. Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology. Mol Genet Metab. 2002;77:150-158.
47. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002; 99:7604-7609.
48. Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003;536:6-11.
49. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007;282:743-751.
50. Chisholm JW, Hong J, Mills SA, et al. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003;44:2039-2048.
51. Sekar N, Veldhuis JD. Involvement of SP1 and SREBP-1a in transcriptional activation of the LDL receptor gene by insulin and IH in cultured porcine granulosa-luteal cells. Am J Physiol Endocrinol Metab. 2004; 287:E128-E135.